Ascendis Pharma A/S
ASND
244 hedge funds and large institutions have $10.1B invested in Ascendis Pharma A/S in 2025 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 77 increasing their positions, 88 reducing their positions, and 24 closing their positions.
125% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 24
16% more capital invested
Capital invested by funds: $8.78B → $10.1B (+$1.37B)
14% more funds holding
Funds holding: 214 → 244 (+30)
1.8% more ownership
Funds ownership: 106.61% → 108.41% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
13% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 88
38% less call options, than puts
Call options by funds: $23.8M | Put options by funds: $38.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$154M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$46.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$46.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$40.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$32.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$64.3M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$52.8M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$38.1M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$27.7M |
| 5 |
BlackRock
New York
|
-$19.4M |
ASND Hedge Fund Activity: Q1 2025 in Review
244 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2025, worth a combined $10.1B — up 16% from $8.78B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ASND positions and 24 closed out — a net gain of 30 holders — while 77 added to existing stakes and 88 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $154M. The largest seller was Camber Capital Management, cutting an estimated $64.3M.
- 244 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2025, up from 214 in Q4 2024.
- Funds reported $10.1B of Ascendis Pharma A/S stock for Q1 2025, up 16% quarter-over-quarter.
- 54 funds opened new Ascendis Pharma A/S positions in Q1 2025 and 24 closed out, a net change of +30 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2025 was Morgan Stanley, an estimated $154M added.
- The largest Ascendis Pharma A/S seller in Q1 2025 was Camber Capital Management, an estimated $64.3M sold.
Based on aggregated 13F filings for Q1 2025.